8-K: Haemonetics Acquires Vivasure Medical for $100M, Bolsters Closure Tech

Haemonetics Corporation announced the acquisition of Vivasure Medical Limited for $100 million, expanding its presence in the percutaneous vessel closure market.

Summary

• Haemonetics Corporation acquired Vivasure Medical Limited, an Ireland-based company specializing in percutaneous vessel closure technology.
• The acquisition cost is $100 million upfront, or approximately $52 million net of previous investments and loans.
• An additional $85 million in contingent consideration is possible, based on sales growth and milestone achievements.
• The transaction was financed using Haemonetics' available cash on hand.
• Vivasure's flagship product, the PerQseal Elite system, uses a bioabsorbable patch for large-bore arteriotomy and venotomy closure.
• The PerQseal Elite system received CE Mark approval in Europe for both arterial and venous indications and submitted a Premarket Approval application to the U.S. FDA in 2025 for arterial closure.
• Clinical results from the ELITE arterial study showed ease of use with no need for pre-close, 0% major complications at thirty-day follow-up, and immediate median time to hemostasis.

Sentiment

Score: 8

Explanation: The acquisition is strategically sound, expands market presence, introduces clinically validated technology, and is financed through available cash, indicating a strong positive outlook for Haemonetics' growth in a key market segment.

Positives

• Acquisition expands Haemonetics' range of closure devices with clinically differentiated technology.
• Bolsters Haemonetics' presence in the large-bore closure market and impact in fast-growing structural heart and endovascular procedures.
• Vivasure's PerQseal Elite system has strong clinical performance and safety data, including 0% major complications at thirty-day follow-up in the ELITE arterial study.
• The PerQseal Elite system offers a sutureless, fully absorbable solution for vessel closure.
• The acquisition leverages Haemonetics' commercial scale and operational synergies.
• Vivasure's PerQseal Elite system received CE Mark approval in Europe for both arterial and venous indications.
• The transaction was financed through available cash on hand, indicating financial strength.

Risks

• Failure to realize the anticipated benefits of the acquisition or the acquisition having an unanticipated impact.
• Haemonetics' ability to accurately predict demand for products and products under development by it or Vivasure.
• Ability to develop strategies to successfully address relevant markets.
• Actual and anticipated achievement of future sales growth and other milestones on which contingent consideration is based.
• Impact of competitive products and pricing.
• Regulatory uncertainties, including in the receipt or timing of regulatory approvals (e.g., U.S. FDA approval for PerQseal Elite).
• Technical innovations that could render products marketed or under development by Haemonetics or Vivasure obsolete.
• Risks related to the use and protection of intellectual property.

Future Outlook

Haemonetics expects the acquisition to bolster its presence in the large-bore closure market and impact in fast-growing structural heart and endovascular procedures. The company aims to leverage its commercial scale and operational synergies to deliver increased value to physicians and hospitals, accelerating the global availability of PerQseal Elite and its clinical benefits.

Management Comments

• "Acquiring Vivasure expands Haemonetics complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures." Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics.
• "With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals." Ken Crowley.
• "Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide." Andrew Glass, Chief Executive Officer of Vivasure Medical Limited.

Industry Context

The acquisition positions Haemonetics more strongly in the competitive and growing large-bore closure market, which is critical for structural heart and endovascular procedures. This market segment is characterized by a need for innovative, safe, and effective solutions for sealing vessel access sites, especially as minimally invasive procedures become more common. Vivasure's technology, with its bioabsorbable patch and strong clinical data, addresses a key need for improved patient outcomes in this space.

Comparison to Industry Standards

• The filing highlights the PerQseal Elite system's "0% major complications at thirty-day follow-up" in the ELITE arterial study, which is a strong safety profile for percutaneous vessel closure devices.
• The "immediate median time to hemostasis" also suggests efficiency compared to traditional methods or other closure devices.
• The "sutureless, fully absorbable solution" differentiates it from some existing closure technologies that may involve sutures or non-absorbable components.
• The ability to seal large-bore (up to 26 F) arteriotomies and venotomies positions it favorably against devices with smaller bore size limitations.

Related Party Transactions

• Haemonetics made previous investments and other loans to Vivasure Medical Limited, which were netted against the upfront acquisition cost.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and long-term growth through strategic expansion into the large-bore closure market.
• Patients: Access to a new, clinically proven, sutureless, and fully absorbable vessel closure technology, potentially leading to improved outcomes and reduced complications.
• Physicians/Hospitals: Access to an advanced closure device (PerQseal Elite system) that offers ease of use and strong safety data, enhancing procedural efficiency and patient care.
• Vivasure Employees: Integration into a larger global medical technology company, providing broader resources and scale to accelerate product availability.

Next Steps

• Accelerate the availability of PerQseal Elite globally.
• Leverage Haemonetics' commercial scale and operational synergies.
• Work towards U.S. FDA approval for the PerQseal Elite arterial closure system.
• Achieve sales growth and other milestones to unlock contingent consideration.

Key Dates

Recommendation

The acquisition of Vivasure Medical is a strategically sound move for Haemonetics, expanding its portfolio with a clinically differentiated and innovative technology in the high-growth large-bore vessel closure market. The PerQseal Elite system's strong clinical data (0% major complications, immediate hemostasis) and regulatory approvals (CE Mark, FDA submission) de-risk the technology. Financing through available cash demonstrates financial prudence. This acquisition positions Haemonetics for enhanced market leadership and future revenue growth, making it an attractive investment for long-term growth.

Keywords

Haemonetics, Vivasure Medical, Acquisition, Medical Technology, Vessel Closure, Percutaneous, Structural Heart, Endovascular, PerQseal Elite, FDA, CE Mark, Bioabsorbable Patch